Cancer treatment runs in parallel with advanced scientific research. FICAN West is the second largest cancer research center in Finland. Its mission is to coordinate cancer research and teaching in the entire West-coast area.
We promote cancer research and the use of up-to-date scientific data within FICAN West and in the whole of Finland.
The Turku Clinical Research Center provides services in the field of health scientific research for researchers of the University of Turku and the Turku special responsibility area.
This takes you to the web page of the Turku Clinical Research centre
Glossary
Special terms are needed when clinical trials are discussed. Laaketutkimukset.fi-website (in Finnish) contains explanations of the most common terms used in clinical trials.
| STUDY CENTER AND PRINCIPAL INVESTIGATOR | STUDY CODE | TITLE OF THE STUDY |
|---|
| GYNECOLOGICAL CANCER | ||
|---|---|---|
| TUCH / Sakari Hietanen | EPIK-O | Phase III randomized study to assess the efficacy and safety of alpelisib in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serous ovarian cancer |
| TUCH / Sakari Hietanen | innovaTV 301 | A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer |
| TUCH / Sakari Hietanen | KEYNOTE-B96 / ENGOT-ov65 | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer |
| LYMPHOMA | ||
|---|---|---|
| TUCH / Sirkku Jyrkkiö | POLAR BEAR | R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years |
| TYKS / Erika Alanne | GENMAB-GCT3013-05 | A randomized, open-label, phase 3 trial of Epcoritamab vs Investigator’s choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma |
| TYKS / Taina Reunamo | InMind | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma |
| BREAST CANCER | ||
|---|---|---|
| Vaasa Central Hospital / Antti Jekunen | CO41101 | A Phase III, Double-blind, Placebo-controlled, Randomized Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
| TUCH / Riikka Huovinen | ZEST | A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY ( |
| TUCH / Riikka Huovinen | lidERA | A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN’S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
| TUCH / Riikka Huovinen | DESTINY – Breast12 | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer |
| BLADDER CANCER | ||
|---|---|---|
| TUCH / Peter Boström | FINNBLADDER 9 | Treatment of stage Ta cancer of the urinary bladder with a high risk of relapse – blue-light cystoscopy and optimized dosage of mitomycin-C. |
| TUCH / Peter Boström | FINNBLADDER 10 | Intravesical Instillation Therapy With Bacillus Calmette-Guérin (BCG) and Sequential BCG and Electromotive Mitomycin-C (EMDA-MCC) in Patients With High-risk Non-muscle-invasive Bladder Carcinoma. |
| TUCH / Peter Boström | CA017-078 | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer |
| RENAL CANCER | ||
| TUCH / Kalle Mattila | MK6482-005 | An Open-label,Randomized Phase 3 Study of MK-6482 Versus Everolimus in participants with Advanced Renal Cell Carcinoma that has progressed after prior PD-1/L1 and VEGFR Tyrosine Kinase Inhibitor Therapy |
| TUCH / Kalle Mattila | MK6482-012 | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination with Belzutifan and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma |
| TUCH / Kalle Mattila | MK6482-011 | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy |
| PROSTATE CANCER | ||
| TUCH / Peter Boström | SPCG-15 | Surgery or radiation therapy in the treatment of locally advanced prostate cancer – open, randomized clinical trial. |
| TUCH / Peter Boström | TALAPRO-3 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER |
| TUCH / Peter Boström | HIFU-PRO-BPH | A early phase 1 non-randomized prospective single-institutional and four arm study to determine the applicability, feasibility and safety of MRI guided transurethral HIFU ablation of prostate separately in each pre-specified group/arm |
| TUCH / Jukka Kemppainen | ADTPSMA2 | The Effect of Androgen Deprivation Therapy on the Expression of Prostate Specific Membrane Antigen (PSMA) Evaluated With 18F-PSMA PET/CT in Treatment naïve Metastatic Prostate Cancer Patients |
| TUCH / Otto Ettala | ESTO-2 | Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy- lipid metabolism as a novel biomarker to predict prostate cancer progression – Phase 3, double-blind randomized clinical trials FinnProstata XV |
| HEAD AND NECK CANCER | ||
|---|---|---|
| TUCH / Heikki Minn | HNLB | Genetic Profiling by Liquid Biopsy for Initial Characterization and Response Monitoring of Head and Neck Squamous Cell Carcinoma |
| HEMATOLOGICAL CANCER | ||
|---|---|---|
| TUCH / Mervi Putkonen | NMSG 23/15 | A Prospective phase 2 study to assess the minimal residual disease after ixazomib plus lenalidomide and dexamethasone (IRd) treatment for newly diagnosed transplant eligible myeloma patients |
| TUCH / Pia Ettala | Ponatinib-3001 | A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) |
| TUCH / Maija Itälä-Remes | HaploMUDStudy | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia With Identical GVHD Prophylaxis – A Randomized Prospective European Trial. |
| MELANOMA | ||
|---|---|---|
| TUCH / Kalle Mattila | RELATIVITY 098 | A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma |
| GASTROINTESTINAL CANCER | ||
|---|---|---|
| Satasairaala Hospital / Kalevi Pulkkanen | SSGXXII | Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence |
| TUCH / Pirita Varpe | RESET | Laparotomy vs Laparoscopy vs Robotic vs TaTME Rectal Surgery Matched Parallel Cohort Trial for High Surgical Risk Cancer Patients, With Mid- to Low Rectal Cancer |
| TUCH / Raija Ristamäki
Vaasa Central Hospital / Pia Österlund | BREAKWATER | AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER |
| TUCH / Raija Ristamäki | KRYSTAL | A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy |
| HEPATOCELLULAR CARCINOMA | ||
|---|---|---|
| TUCH / Eetu Heervä | IMBrave251 | A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB |
| LUNG CANCER | ||
|---|---|---|
| TUCH / Maria Silvoniemi and Vaasa Central Hospital / Antti Jekunen | ASTEROID | Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) |
| TUCH / Maria Silvoniemi | DART | A study of Durvalumab, a type of immunotherapy, for treatment of patients with non-small cell lung cancer with positive or negative PD-L1 expression, following chemotherapy and radiotherapy |
| TUCH / Maria Silvoniemi | MK7684A-008 | A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer |
| TUCH / Maria Silvonimei | MO43576/IMscin002 | A RANDOMIZED, MULTICENTER, OPEN-LABEL CROSS-OVER STUDY TO EVALUATE PARTICIPANT AND HEALTHCARE PROFESSIONAL REPORTED PREFERENCE FOR SUBCUTANEOUS ATEZOLIZUMAB COMPARED WITH INTRAVENOUS ATEZOLIZUMAB FORMULATION IN PARTICIPANTS WITH NONSMALL CELL LUNG CANCER |
| OTHER | ||
|---|---|---|
| TUCH / Kalle Mattila | PD-1 Heart | Predictive clinical, imaging and laboratory biomarkers of cardiac toxicity related to anti-programmed death (PD)-1 therapies |
| TUCH / Panu Jaakkola | MATINS | A phase I/II open-label, three part, dose-finding and separate cohort expansion trial to assess the safety, tolerability and preliminary efficacy of repeated doses of CLEVER-1 antibody FP-1305 in subjects with advanced solid tumours |
| PEDIATRIC | ||
|---|---|---|
| TUCH / Päivi Lähteenmäki | IntreALL 2010 HR | International Study for Treatment of High Risk Childhood Relapsed ALL 2010, A randomized Phase II Study Conducted by the Resistant Disease Committee of the International BFM Study Group |
| TUCH / Päivi Lähteenmäki | NOPHo-DBH AML 2012 | Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years |
| TUCH / Päivi Lähteenmäki | ALL Together | A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL), |
| TUCH / Päivi Lähteenmäki | LBL 2018 | International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma |
| TUCH / Päivi Lähteenmäki | SIOP PNET 5-MB | AN INTERNATIONAL PROSPECTIVE STUDY ON CLINICALLY STANDARD-RISK MEDULLOBLASTOMA IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH LOW-RISK BIOLOGICAL PROFILE (PNET 5 MB – LR) OR AVERAGE-RISK BIOLOGICAL PROFILE |
| TUCH / Päivi Lähteenmäki | NHL 2013 | Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents |
| TUCH / Miia Mokka | TEDDI | Radiotherapy Delivery in Deep Inspiration for Pediatric Patients |
| TUCH / Päivi Lähteenmäki | INFORM | INdividualized Therapy FOr Relapsed Malignancies in Childhood |
| TUCH / Päivi Lähteenmäki | rEEcur | International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma |
